ClinicalTrials.gg
CompletedNCT04590586COMMUNITYUpdated Jun 29, 2022Results posted

Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

A Phase 3 interventional study of Standard of care and Apremilast in COVID-19, sponsored by Amgen. Completed at 59 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-29.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
515
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
303rd of 1,321
515 · median 91
Started
2020
with 817 others
Phase 3
174 of 1,859
11 open now
Registered
749th of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 303rd largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 174 in phase 3, and was the 749th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the time to confirmed clinical recovery in participants hospitalized with COVID-19. Candidate agents will be evaluated frequently for efficacy and safety, with candidate agents being added to and/or removed from the study on an ongoing basis, depending on the results of their evaluation.

Read the detailed description

This adaptive, randomized, placebo-controlled platform study is designed to rapidly assess multiple candidate agents as treatments for COVID-19 in hospitalized patients. Candidate agents will be evaluated frequently (through ongoing monitoring) for futility and safety, with candidate agents being added to and/or removed from the study on an ongoing basis, depending on the results of their evaluation.

For inclusion, participants will need to be hospitalized with a clinical status of Grade 2 to Grade 5, as defined by the following Clinical Severity Status 8-Point Ordinal Scale:

  1. Death
  2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
  3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices
  4. Hospitalized, requiring supplemental oxygen
  5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)
  6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care
  7. Not hospitalized, limitation on activities and/or requiring home oxygen
  8. Not hospitalized, no limitations on activities

Participants will be randomized equally to either the candidate agent plus standard of care (SoC) or placebo plus SoC in a double-blind fashion. Participants who are randomized to placebo plus SoC will subsequently be randomized equally to a matching placebo corresponding to an available agent whose sub-protocol the patient qualified for (ie, a 2-stage randomization). Each participant in the placebo plus SoC group will only receive one type of placebo. Randomization will be stratified by baseline clinical severity of 2 on the 8-point ordinal scale (yes/no) and remdesivir use at baseline (yes/no).

The study will evaluate each candidate agent separately as an add-on to the SoC to assess safety and efficacy. The comparator group for a candidate agent will include participants randomized to the placebo arm of any sub-protocol according to the following conditions:

  • Apremilast sub-protocol: participants who were enrolled concurrently to apremilast and who would have been eligible for the apremilast sub-protocol.
  • Lanadelumab sub-protocol: at a site where at least one participant was randomized to either lanadelumab active or placebo arms.
  • Zilucoplan sub-protocol: at a site where at least one participant was randomized to either the zilucoplan active or placebo arms.
03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • SARS-CoV-2
  • Severe acute respiratory syndrome coronavirus 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (≥18 years of age) with active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection confirmed by laboratory tests and/or point of care tests (eg, commercial or public health assay, which is approved for emergency use). If no diagnostic test results are available that have been obtained during the previous 72 hours, then a test should be performed as part of the screening assessment.
  • A score of Grade 2 (hospitalized, on invasive mechanical ventilation or ECMO), Grade 3 (hospitalized, on noninvasive ventilation or high-flow oxygen devices), Grade 4 (hospitalized, requiring supplemental oxygen), or Grade 5 (hospitalized, not requiring supplemental oxygen, requiring ongoing medical care [COVID-19 related or otherwise]), as defined by an 8 point ordinal scale.
  • Male participants:

    • A male participant must agree to use during the treatment period and for at least 6 weeks after the last dose of study treatment and refrain from donating sperm during this period.
  • Female participants:

    • A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:
    • Not a woman of (WOCBP). OR
    • A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 6 weeks after the last dose of study treatment.
  • Ability to provide signed by the study participant or legally authorized representative.
  • Ability and willingness to participate in telephone/telemedicine follow-up visits if needed.
  • Zilucoplan only: Antibiotic prophylaxis: all participants must be willing to take antibiotic prophylaxis concomitantly, starting with the first dose of zilucoplan or placebo.

Exclusion criteria

Exclusion Criteria:

  • Participant has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the participant (eg, compromise their well-being) or that could prevent, limit, or confound the protocol-specified assessments (eg, participants unable to swallow study medication tablets).
  • Stage 4 severe chronic kidney disease or requiring dialysis.
  • Screening 12-lead (ECG) with a measurable according to Fridericia correction (QTcF) ≥ 500 ms.
  • Anticipated transfer to another hospital that is not a study center within 72 hours.
  • Participants who are currently pregnant or who are not willing to discontinue breastfeeding.
  • Participants participating in another clinical study of an medicinal product or other unapproved (or investigational) treatment for COVID-19.
  • Active tuberculosis or a history of incompletely treated tuberculosis.
  • Active, uncontrolled systemic bacterial or fungal infection(s).
  • Apremilast only: Current treatment with apremilast, or another agent of similar mechanism of action, for any indication within 1 week prior to first dose of investigational product.
  • Apremilast only: Concurrent use at screening or randomization of cytochrome P450 (CYP)3A inducers (eg, rifampin, phenobarbital, carbamazepine) within 1 week prior to first dose of investigational product.
  • Apremilast only: Known to apremilast or any in formulation.
  • Lanadelumab only: Known or suspected hypersensitivity to lanadelumab or any of its excipients.
  • Lanadelumab only: Previous (within 3 months prior to baseline) or current use of immunomodulators (eg, methotrexate, azathioprine, 6-mercaptopurine, tumor necrosis factor [TNF] α inhibitor, Janus kinase [JAK] inhibitor, alpha-integrin inhibitor).
  • Lanadelumab only: Known or suspected venous thromboembolism.
  • Lanadelumab only: Previous (within 3 months [or 5 half-lives, whichever is greater] of screening) or current use of plasma kallikrein (pKal) inhibitor or bradykinin receptor blocker.
  • Zilucoplan only: Participants with unresolved or suspected infection with Neisseria meningitidis or a past history of N. meningitidis (eg, in a complement-deficient patient).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
515 participants (actual)

Study arms

  • Experimental
    Apremilast + Standard of Care

    Participants will be randomized to receive 30 mg apremilast orally twice a day (BID) in addition to standard of care treatment for 14 days or until hospital discharge, death, or discontinuation of investigational product, whichever occurred first.

    Drug: Standard of care · Drug: Apremilast

  • Placebo comparator
    Apremilast Placebo + Standard of Care

    Participants will be randomized to receive matching placebo to apremilast orally twice a day in addition to standard of care treatment for 14 days or until hospital discharge, death, or discontinuation of investigational product, whichever occurred first.

    Drug: Standard of care · Drug: Apremilast placebo

  • Experimental
    Lanadelumab + Standard of Care

    Participants will be randomized to receive lanadelumab 300 mg by intravenous infusion on Day 1, and a second dose administered on Day 4 in addition to standard of care.

    Drug: Standard of care · Drug: Lanadelumab

  • Placebo comparator
    Lanadelumab Placebo + Standard of Care

    Participants will be randomized to receive placebo to lanadelumab by intravenous infusion on Day 1, and a second dose administered on Day 4 in addition to standard of care.

    Drug: Standard of care · Drug: Lanadelumab placebo

  • Experimental
    Zilucoplan + Standard of Care

    Participants will be randomized to receive 32.4 mg zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment in addition to standard of care.

    Drug: Standard of care · Drug: Zilucoplan

  • Placebo comparator
    Zilucoplan Placebo + Standard of Care

    Participants will be randomized to receive placebo to zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment in addition to standard of care.

    Drug: Standard of care · Drug: Zilucoplan placebo

Interventions

  • DrugStandard of care

    Standard of care (SoC) treatment for COVID-19 infection in line with institutional practice. The SoC may change as new information becomes available about treating COVID-19.

  • Apremilast administered orally as a tablet.

    Also known as: Otezla

  • DrugApremilast placebo

    Matching apremilast placebo administered orally as a tablet.

  • Lanadelumab administered as an intravenous (IV) infusion.

    Also known as: TAKHZYRO™, TAK-743

  • DrugLanadelumab placebo

    Matching lanadelumab placebo (normal saline) administered as an intravenous (IV) infusion.

  • Zilucoplan administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.

  • DrugZilucoplan placebo

    Matching zilucoplan placebo administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.

06

What researchers measure

Primary outcomes

  1. Lanadelumab Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29

    Confirmed clinical recovery means the participant is fit for discharge from hospital, defined by achieving a score of 6 (hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care), 7 (not hospitalized, limitation on activities and/or requiring home oxygen), or 8 (not hospitalized, no limitations on activities) on the clinical severity status 8-point ordinal scale, without being re-hospitalized prior to Day 29. The Kaplan-Meier estimate of the time to confirmed clinical recovery through Day 29, without re-hospitalization through Day 29, was calculated from Study Day 1 to the earliest date on which the participant had a score of 6, 7, or 8 up to Day 29. Participants who never reached a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale before or on Day 29 were censored at Day 29. Participants who discontinued from the study before or on Day 29 were censored at time of discontinuation from study.

    Time frame: Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29

  2. Apremilast Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29

    Confirmed clinical recovery means the participant is fit for discharge from hospital, defined by achieving a score of 6 (hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care), 7 (not hospitalized, limitation on activities and/or requiring home oxygen), or 8 (not hospitalized, no limitations on activities) on the clinical severity status 8-point ordinal scale, without being re-hospitalized prior to Day 29. The Kaplan-Meier estimate of the time to confirmed clinical recovery through Day 29, without re-hospitalization through Day 29, was calculated from Study Day 1 to the earliest date on which the participant had a score of 6, 7, or 8 up to Day 29. Participants who never reached a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale before or on Day 29 were censored at Day 29. Participants who discontinued from the study before or on Day 29 were censored at time of discontinuation from study.

    Time frame: Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29

  3. Zilucoplan Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29

    Confirmed clinical recovery means the participant is fit for discharge from hospital, defined by achieving a score of 6 (hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care), 7 (not hospitalized, limitation on activities and/or requiring home oxygen), or 8 (not hospitalized, no limitations on activities) on the clinical severity status 8-point ordinal scale, without being re-hospitalized prior to Day 29. The Kaplan-Meier estimate of the time to confirmed clinical recovery through Day 29, without re-hospitalization through Day 29, was calculated from Study Day 1 to the earliest date on which the participant had a score of 6, 7, or 8 up to Day 29. Participants who never reached a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale before or on Day 29 were censored at Day 29. Participants who discontinued from the study before or on Day 29 were censored at time of discontinuation from study.

    Time frame: Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29

Secondary outcomes

  1. Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29

    Oxygen-free recovery at Day 29 is defined as being alive, discharged, and not receiving supplemental oxygen at Day 29. Participants who reached a score of 7 on the ordinal scale for clinical severity who were discharged to hospice care before or on Day 29 were considered as not discharged at Day 29. Participants with a missing oxygen-free recovery status at Day 29 were considered as not having an oxygen-free recovery.

    Time frame: Day 29

  2. Lanadelumab Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29

    Fit for discharge is defined as achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with an ordinal scale score of 7 must not have been discharged to hospice care to be considered as fit for discharge. Participants with a missing clinical severity score at Day 29 were considered as not having met the event at Day 29. The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities

    Time frame: Baseline (Day 1) and Day 29

  3. Lanadelumab Sub-protocol: Percentage of Participants Who Died Before or on Day 29

    All-cause mortality is death due to any cause. Participants with an unknown alive/death status on Day 29 were considered alive for this analysis, with the exception of patients with a score of 7 who were discharged to hospice care before or on Day 29.

    Time frame: Day 1 to Day 29

  4. Lanadelumab Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29

    The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities Participants with a score of 7 who were discharged to hospice care are counted with participants with a score of 1 (death) for this endpoint.

    Time frame: Day 8, Day 15, and Day 29

  5. Lanadelumab Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-point Ordinal Scale From Baseline to Day 29

    The worst post-baseline score (lower scores are worse) through Day 29 in the clinical severity status 8-point ordinal scale, derived from all scores recorded after baseline up to and including Day 29. Participants with a score of 7 discharged to hospice care are considered as having a score of 1 (death) instead of a score of 7 for this endpoint. The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities

    Time frame: Day 2 to Day 29

  6. Lanadelumab Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29

    Number of ICU days is the sum of the duration of any episode of ICU admission between Day 1 and Day 29, both inclusive. The number of ICU days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30 (worst possible outcome).

    Time frame: Day 1 to Day 29

  7. Lanadelumab Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29

    Number of invasive mechanical ventilator days is the sum of the duration of any episode of invasive mechanical ventilator admission between Day 1 and Day 29, both inclusive. The number of invasive mechanical ventilator days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30.

    Time frame: Day 1 to Day 29

  8. Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery by Days 8, 15, and 29

    Clinical recovery is defined as being fit for discharge, i.e., the achievement of a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who discontinued the study on or before Days 8, 15, or 29 or with a missing clinical recovery status were considered as not having clinical recovery at each respective time point. Clinical severity status 8-point ordinal scale: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities

    Time frame: Day 8, Day 15, and Day 29

  9. Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery

    Sustained clinical recovery is defined as being fit for discharge (achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale) by Day 29, without re-hospitalization by Day 60. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who died or discontinued from study or with a missing clinical recovery status at Day 60 were not considered having sustained clinical recovery. Clinical severity status 8-point ordinal scale: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities

    Time frame: Day 60

  10. Lanadelumab Sub-protocol: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to study treatment. A TEAE is an AE that occurs after the first dose of study drug. A Serious AE is any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, resulted in persistent disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may jeopardize the patient or require intervention to prevent an outcome listed above. The Investigator assessed the intensity of each AE according to the Common Terminology Criteria for Adverse Events (CTCAE): * Grade 1 Mild; asymptomatic or mild symptoms; * Grade 2 Moderate; minimal, local or noninvasive intervention indicated; * Grade 3 Severe or medically significant, not immediately life-threatening; * Grade 4 Life-threatening; urgent intervention indicated; * Grade 5 Death due to AE.

    Time frame: From first dose of study drug to end of study (Day 60)

  11. Apremilast Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29

    Oxygen-free recovery at Day 29 is defined as being alive, discharged, and not receiving supplemental oxygen at Day 29. Participants who reached a score of 7 on the ordinal scale for clinical severity who were discharged to hospice care before or on Day 29 were considered as not discharged at Day 29. Participants with a missing oxygen-free recovery status at Day 29 were considered as not having an oxygen-free recovery.

    Time frame: Day 29

  12. Apremilast Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29

    Fit for discharge is defined as achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with an ordinal scale score of 7 must not have been discharged to hospice care to be considered as fit for discharge. Participants with a missing clinical severity score at Day 29 were considered as not having met the event at Day 29. The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities

    Time frame: Baseline (Day 1) and Day 29

  13. Apremilast Sub-protocol: Percentage of Participants Who Died Before or on Day 29

    All-cause mortality is death due to any cause. Participants with an unknown alive/death status on Day 29 were considered alive for this analysis, with the exception of patients with a score of 7 who were discharged to hospice care before or on Day 29.

    Time frame: Day 1 to Day 29

  14. Apremilast Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29

    The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities Participants with a score of 7 who were discharged to hospice care are counted with participants with a score of 1 (death) for this endpoint.

    Time frame: Day 8, Day 15, and Day 29

  15. Apremilast Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-Point Ordinal Scale From Baseline to Day 29

    The worst post-baseline score (lower scores are worse) through Day 29 in the clinical severity status 8-point ordinal scale, derived from all scores recorded after baseline up to and including Day 29. Participants with a score of 7 discharged to hospice care are considered as having a score of 1 (death) instead of a score of 7 for this endpoint. The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities

    Time frame: Day 2 to Day 29

  16. Apremilast Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29

    Number of ICU days is the sum of the duration of any episode of ICU admission between Day 1 and Day 29, both inclusive. The number of ICU days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30 (worst possible outcome).

    Time frame: Day 1 to Day 29

  17. Apremilast Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29

    Number of invasive mechanical ventilator days is the sum of the duration of any episode of invasive mechanical ventilator admission between Day 1 and Day 29, both inclusive. The number of invasive mechanical ventilator days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30.

    Time frame: Day 1 to Day 29

  18. Apremilast Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery at Days 8, 15, and 29

    Clinical recovery is defined as being fit for discharge, i.e., the achievement of a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who discontinued the study on or before Days 8, 15, or 29 or with a missing clinical recovery status were considered as not having clinical recovery at each respective time point. Clinical severity status 8-point ordinal scale: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities

    Time frame: Day 8, Day 15, and Day 29

  19. Apremilast Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery

    Sustained clinical recovery is defined as being fit for discharge (achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale) by Day 29, without re-hospitalization by Day 60. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who died or discontinued from study or with a missing clinical recovery status at Day 60 were not considered having sustained clinical recovery. Clinical severity status 8-point ordinal scale: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities

    Time frame: Day 60

  20. Apremilast Sub-protocol: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to study treatment. A TEAE is an AE that occurs after the first dose of study drug. A serious AE is any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, resulted in persistent disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may jeopardize the patient or require intervention to prevent an outcome listed above. The Investigator assessed the intensity of each AE according to the CTCAE grades: * Grade 1 Mild; asymptomatic or mild symptoms; * Grade 2 Moderate; minimal, local or noninvasive intervention indicated; * Grade 3 Severe or medically significant, not immediately life-threatening; * Grade 4 Life-threatening; urgent intervention indicated; * Grade 5 Death due to AE.

    Time frame: From first dose of study drug to end of study (Day 60)

  21. Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29

    Oxygen-free recovery at Day 29 is defined as being alive, discharged, and not receiving supplemental oxygen at Day 29. Participants who reached a score of 7 on the ordinal scale for clinical severity who were discharged to hospice care before or on Day 29 were considered as not discharged at Day 29. Participants with a missing oxygen-free recovery status at Day 29 were considered as not having an oxygen-free recovery.

    Time frame: Day 29

  22. Zilucoplan Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29

    Fit for discharge is defined as achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with an ordinal scale score of 7 must not have been discharged to hospice care to be considered as fit for discharge. Participants with a missing clinical severity score at Day 29 were considered as not having met the event at Day 29. The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities

    Time frame: Baseline (Day 1) and Day 29

  23. Zilucoplan Sub-protocol: Percentage of Participants Who Died Before or on Day 29

    All-cause mortality is death due to any cause. Participants with an unknown alive/death status on Day 29 were considered alive for this analysis, with the exception of patients with a score of 7 who were discharged to hospice care before or on Day 29.

    Time frame: Day 1 to Day 29

  24. Zilucoplan Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29

    The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities Participants with a score of 7 who were discharged to hospice care are counted with participants with a score of 1 (death) for this endpoint.

    Time frame: Day 8, Day 15, and Day 29

  25. Zilucoplan Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-Point Ordinal Scale From Baseline to Day 29

    The worst post-baseline score (lower scores are worse) through Day 29 in the clinical severity status 8-point ordinal scale scores, derived from all scores recorded after baseline up to and including Day 29. Participants with a score of 7 discharged to hospice care were considered as having a score of 1 (death) instead of a score of 7 for this endpoint. The clinical severity status 8-point ordinal scale scores scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities

    Time frame: Day 2 to Day 29

  26. Zilucoplan Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29

    Number of ICU days is the sum of the duration of any episode of ICU admission between Day 1 and Day 29, both inclusive. The number of ICU days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30 (worst possible outcome).

    Time frame: Day 1 to Day 29

  27. Zilucoplan Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29

    Number of invasive mechanical ventilator days is the sum of the duration of any episode of invasive mechanical ventilator admission between Day 1 and Day 29, both inclusive. The number of invasive mechanical ventilator days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30.

    Time frame: Day 1 to Day 29

  28. Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery by Days 8, 15, and 29

    Clinical recovery is defined as being fit for discharge, i.e., the achievement of a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who discontinued the study on or before Days 8, 15, or 29 or with a missing clinical recovery status were considered as not having clinical recovery at each respective time point. Clinical severity status 8-point ordinal scale: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities

    Time frame: Day 8, Day 15, and Day 29

  29. Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery

    Sustained clinical recovery is defined as being fit for discharge (achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale) by Day 29, without re-hospitalization by Day 60. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who died or discontinued from study or with a missing clinical recovery status at Day 60 were not considered having sustained clinical recovery. Clinical severity status 8-point ordinal scale: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities

    Time frame: Day 60

  30. Zilucoplan Sub-protocol: Number of Participants With Treatment-emergent Adverse Events

    An adverse event is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to study treatment. A TEAE is an AE that occurs after the first dose of study drug. A serious AE is any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, resulted in persistent disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may jeopardize the patient or require intervention to prevent an outcome listed above. The Investigator assessed the intensity of each AE according to the CTCAE grades: * Grade 1 Mild; asymptomatic or mild symptoms; * Grade 2 Moderate; minimal, local or noninvasive intervention indicated; * Grade 3 Severe or medically significant, not immediately life-threatening; * Grade 4 Life-threatening; urgent intervention indicated; * Grade 5 Death due to AE.

    Time frame: From first dose of study drug to end of study (Day 60)

07

Results

Posted Jun 29, 2022

Participant flow

This adaptive platform study consisted of 3 sub-protocols, each designed to assess a candidate agent as treatment for coronavirus disease 2019 (COVID-19) in hospitalized adult patients who had severe infection with acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19. The control group for a candidate agent includes participants randomized to any matching placebo for a candidate agent if certain criteria were met (shared placebo).

Participant flow — Overall Study
MilestoneLanadelumab + Standard of CareLanadelumab Placebo + Standard of CareApremilast + Standard of CareApremilast Placebo + Standard of CareZilucoplan + Standard of CareZilucoplan Placebo + Standard of Care
Started2811941841008
Received study drug271189182957
Full analysis set283419419010075
Completed150139138704
Not completed1315546304
Withdrew: Death713734193
Withdrew: Lost to follow-up30111160
Withdrew: Withdrawal by subject006030
Withdrew: Other301121

Outcome measures

PrimaryLanadelumab Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29

Confirmed clinical recovery means the participant is fit for discharge from hospital, defined by achieving a score of 6 (hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care), 7 (not hospitalized, limitation on activities and/or requiring home oxygen), or 8 (not hospitalized, no limitations on activities) on the clinical severity status 8-point ordinal scale, without being re-hospitalized prior to Day 29. The Kaplan-Meier estimate of the time to confirmed clinical recovery through Day 29, without re-hospitalization through Day 29, was calculated from Study Day 1 to the earliest date on which the participant had a score of 6, 7, or 8 up to Day 29. Participants who never reached a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale before or on Day 29 were censored at Day 29. Participants who discontinued from the study before or on Day 29 were censored at time of discontinuation from study.

Time frame:
Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29
Reported as:
Median · days
Lanadelumab Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29
daysLanadelumab + Standard of CareLanadelumab Placebo Control
Lanadelumab Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 2910.0 (5.00 to NA)15.5 (8.00 to NA)
Statistical analysis
  • Lanadelumab + Standard of Care vs Lanadelumab Placebo Control · Stratified log-rank test · p = 0.6672 · Hazard ratio (hr): 1.17 · 95% CI 0.59 to 2.35Hazard ratio (Lanadelumab vs. placebo) from a Cox regression model including baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.
PrimaryApremilast Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29

Confirmed clinical recovery means the participant is fit for discharge from hospital, defined by achieving a score of 6 (hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care), 7 (not hospitalized, limitation on activities and/or requiring home oxygen), or 8 (not hospitalized, no limitations on activities) on the clinical severity status 8-point ordinal scale, without being re-hospitalized prior to Day 29. The Kaplan-Meier estimate of the time to confirmed clinical recovery through Day 29, without re-hospitalization through Day 29, was calculated from Study Day 1 to the earliest date on which the participant had a score of 6, 7, or 8 up to Day 29. Participants who never reached a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale before or on Day 29 were censored at Day 29. Participants who discontinued from the study before or on Day 29 were censored at time of discontinuation from study.

Time frame:
Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29
Reported as:
Median · days
Apremilast Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29
daysApremilast + Standard of CareApremilast Placebo Control
Apremilast Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 2914.0 (11.00 to 15.00)14.0 (11.00 to 15.00)
Statistical analysis
  • Apremilast + Standard of Care vs Apremilast Placebo Control · Stratified log-rank test · p = 0.8779 · Hazard ratio (hr): 0.97 · 95% CI 0.77 to 1.24Hazard ratio (apremilast vs. placebo) from a Cox regression model including baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.
PrimaryZilucoplan Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29

Confirmed clinical recovery means the participant is fit for discharge from hospital, defined by achieving a score of 6 (hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care), 7 (not hospitalized, limitation on activities and/or requiring home oxygen), or 8 (not hospitalized, no limitations on activities) on the clinical severity status 8-point ordinal scale, without being re-hospitalized prior to Day 29. The Kaplan-Meier estimate of the time to confirmed clinical recovery through Day 29, without re-hospitalization through Day 29, was calculated from Study Day 1 to the earliest date on which the participant had a score of 6, 7, or 8 up to Day 29. Participants who never reached a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale before or on Day 29 were censored at Day 29. Participants who discontinued from the study before or on Day 29 were censored at time of discontinuation from study.

Time frame:
Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29
Reported as:
Median · days
Zilucoplan Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29
daysZilucoplan + Standard of CareZilucoplan Placebo Control
Zilucoplan Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 2914.0 (11.00 to 22.0)15.0 (11.00 to 22.00)
SecondaryLanadelumab Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29

Oxygen-free recovery at Day 29 is defined as being alive, discharged, and not receiving supplemental oxygen at Day 29. Participants who reached a score of 7 on the ordinal scale for clinical severity who were discharged to hospice care before or on Day 29 were considered as not discharged at Day 29. Participants with a missing oxygen-free recovery status at Day 29 were considered as not having an oxygen-free recovery.

Time frame:
Day 29
Reported as:
Number · percentage of participants
Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29
percentage of participantsLanadelumab + Standard of CareLanadelumab Placebo Control
Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 2952.0 (31.31 to 72.20)56.7 (37.43 to 74.54)
SecondaryLanadelumab Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29

Fit for discharge is defined as achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with an ordinal scale score of 7 must not have been discharged to hospice care to be considered as fit for discharge. Participants with a missing clinical severity score at Day 29 were considered as not having met the event at Day 29. The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities

Time frame:
Baseline (Day 1) and Day 29
Reported as:
Number · percentage of participants
Lanadelumab Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29
percentage of participantsLanadelumab + Standard of CareLanadelumab Placebo Control
Lanadelumab Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 2972.0 (50.61 to 87.93)63.3 (43.86 to 80.07)
SecondaryLanadelumab Sub-protocol: Percentage of Participants Who Died Before or on Day 29

All-cause mortality is death due to any cause. Participants with an unknown alive/death status on Day 29 were considered alive for this analysis, with the exception of patients with a score of 7 who were discharged to hospice care before or on Day 29.

Time frame:
Day 1 to Day 29
Reported as:
Number · percentage of participants
Lanadelumab Sub-protocol: Percentage of Participants Who Died Before or on Day 29
percentage of participantsLanadelumab + Standard of CareLanadelumab Placebo Control
Lanadelumab Sub-protocol: Percentage of Participants Who Died Before or on Day 2932.0 (14.95 to 53.50)30.0 (14.73 to 49.40)
SecondaryLanadelumab Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29

The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities Participants with a score of 7 who were discharged to hospice care are counted with participants with a score of 1 (death) for this endpoint.

Time frame:
Day 8, Day 15, and Day 29
Reported as:
Count of participants · Participants
Lanadelumab Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29
ParticipantsLanadelumab + Standard of CareLanadelumab Placebo Control
Day 8 — 1 (Death or discharged to hospice care)33
Day 8 — 2 (Hospitalized on invasive mechanical ventilation or ECMO)46
Day 8 — 3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices)34
Day 8 — 4 (Hospitalized, requiring supplemental oxygen)26
Day 8 — 5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care)10
Day 8 — 6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care)11
Day 8 — 7 (Not hospitalized, limitation on activities and/or requiring home oxygen)23
Day 8 — 8 (Not hospitalized, no limitations on activities)87
Day 8 — Missing10
Day 15 — 1 (Death or discharged to hospice care)37
Day 15 — 2 (Hospitalized on invasive mechanical ventilation or ECMO)34
Day 15 — 3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices)10
Day 15 — 4 (Hospitalized, requiring supplemental oxygen)02
Day 15 — 5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care)00
Day 15 — 6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care)01
Day 15 — 7 (Not hospitalized, limitation on activities and/or requiring home oxygen)53
Day 15 — 8 (Not hospitalized, no limitations on activities)1213
Day 15 — Missing10
Day 29 — 1 (Death or discharged to hospice care)79
Day 29 — 2 (Hospitalized on invasive mechanical ventilation or ECMO)02
Day 29 — 3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices)00
Day 29 — 4 (Hospitalized, requiring supplemental oxygen)00
Day 29 — 5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care)00
Day 29 — 6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care)00
Day 29 — 7 (Not hospitalized, limitation on activities and/or requiring home oxygen)56
Day 29 — 8 (Not hospitalized, no limitations on activities)1213
Day 29 — Missing10
SecondaryLanadelumab Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-point Ordinal Scale From Baseline to Day 29

The worst post-baseline score (lower scores are worse) through Day 29 in the clinical severity status 8-point ordinal scale, derived from all scores recorded after baseline up to and including Day 29. Participants with a score of 7 discharged to hospice care are considered as having a score of 1 (death) instead of a score of 7 for this endpoint. The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities

Time frame:
Day 2 to Day 29
Reported as:
Count of participants · Participants
Lanadelumab Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-point Ordinal Scale From Baseline to Day 29
ParticipantsLanadelumab + Standard of CareLanadelumab Placebo Control
1 (Death or discharged to hospice care)89
2 (Hospitalized on invasive mechanical ventilation or ECMO)04
3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices)65
4 (Hospitalized, requiring supplemental oxygen)811
5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care)10
6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care)00
7 (Not hospitalized, limitation on activities and/or requiring home oxygen)00
8 (Not hospitalized, no limitations on activities)11
Missing10
SecondaryLanadelumab Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29

Number of ICU days is the sum of the duration of any episode of ICU admission between Day 1 and Day 29, both inclusive. The number of ICU days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30 (worst possible outcome).

Time frame:
Day 1 to Day 29
Reported as:
Count of participants · Participants
Lanadelumab Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29
ParticipantsLanadelumab + Standard of CareLanadelumab Placebo Control
0 days1310
1 day11
3 days01
5 days01
6 days02
8 days13
11 days20
13 days11
15 days01
21 days01
30 days (death or discharged to hospice care)79
SecondaryLanadelumab Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29

Number of invasive mechanical ventilator days is the sum of the duration of any episode of invasive mechanical ventilator admission between Day 1 and Day 29, both inclusive. The number of invasive mechanical ventilator days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30.

Time frame:
Day 1 to Day 29
Reported as:
Count of participants · Participants
Lanadelumab Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29
ParticipantsLanadelumab + Standard of CareLanadelumab Placebo Control
0 days1718
6 days01
16 days01
24 days01
30 days (death or discharged to hospice care)89
SecondaryLanadelumab Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery by Days 8, 15, and 29

Clinical recovery is defined as being fit for discharge, i.e., the achievement of a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who discontinued the study on or before Days 8, 15, or 29 or with a missing clinical recovery status were considered as not having clinical recovery at each respective time point. Clinical severity status 8-point ordinal scale: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities

Time frame:
Day 8, Day 15, and Day 29
Reported as:
Number · percentage of participants
Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery by Days 8, 15, and 29
percentage of participantsLanadelumab + Standard of CareLanadelumab Placebo Control
Day 844.0 (24.40 to 65.07)36.7 (19.93 to 56.14)
Day 1556.0 (34.93 to 75.60)56.7 (37.43 to 75.54)
Day 2960.0 (38.67 to 78.87)63.3 (43.86 to 80.07)
SecondaryLanadelumab Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery

Sustained clinical recovery is defined as being fit for discharge (achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale) by Day 29, without re-hospitalization by Day 60. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who died or discontinued from study or with a missing clinical recovery status at Day 60 were not considered having sustained clinical recovery. Clinical severity status 8-point ordinal scale: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities

Time frame:
Day 60
Reported as:
Number · percentage of participants
Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery
percentage of participantsLanadelumab + Standard of CareLanadelumab Placebo Control
Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery40.0 (21.13 to 61.33)56.7 (37.43 to 74.54)
SecondaryLanadelumab Sub-protocol: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to study treatment. A TEAE is an AE that occurs after the first dose of study drug. A Serious AE is any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, resulted in persistent disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may jeopardize the patient or require intervention to prevent an outcome listed above. The Investigator assessed the intensity of each AE according to the Common Terminology Criteria for Adverse Events (CTCAE): * Grade 1 Mild; asymptomatic or mild symptoms; * Grade 2 Moderate; minimal, local or noninvasive intervention indicated; * Grade 3 Severe or medically significant, not immediately life-threatening; * Grade 4 Life-threatening; urgent intervention indicated; * Grade 5 Death due to AE.

Time frame:
From first dose of study drug to end of study (Day 60)
Reported as:
Count of participants · Participants
Lanadelumab Sub-protocol: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsLanadelumab + Standard of CareLanadelumab Placebo ControlLanadelumab Placebo + Standard of Care
Any treatment-emergent adverse event (TEAE)17221
TEAE with a CTCAE grade ≥ 311181
Serious TEAE11181
TEAE leading to dose modification230
TEAE leading to discontinuation of study drug150
SecondaryApremilast Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29

Oxygen-free recovery at Day 29 is defined as being alive, discharged, and not receiving supplemental oxygen at Day 29. Participants who reached a score of 7 on the ordinal scale for clinical severity who were discharged to hospice care before or on Day 29 were considered as not discharged at Day 29. Participants with a missing oxygen-free recovery status at Day 29 were considered as not having an oxygen-free recovery.

Time frame:
Day 29
Reported as:
Number · percentage of participants
Apremilast Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29
percentage of participantsApremilast + Standard of CareApremilast Placebo Control
Apremilast Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 2959.863.7
Statistical analysis
  • Apremilast + Standard of Care vs Apremilast Placebo Control · Regression, Logistic · p = 0.3773 · Risk difference (rd): -4.0 · 95% CI -12.9 to 4.9Risk difference is from a logistic regression including the baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.
  • Apremilast + Standard of Care vs Apremilast Placebo Control · Odds ratio (or): 0.82 · 95% CI 0.52 to 1.28Odds ratio (apremilast vs. placebo) is from a logistic regression including the baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.
SecondaryApremilast Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29

Fit for discharge is defined as achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with an ordinal scale score of 7 must not have been discharged to hospice care to be considered as fit for discharge. Participants with a missing clinical severity score at Day 29 were considered as not having met the event at Day 29. The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities

Time frame:
Baseline (Day 1) and Day 29
Reported as:
Number · percentage of participants
Apremilast Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29
percentage of participantsApremilast + Standard of CareApremilast Placebo Control
Apremilast Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 2974.777.9
Statistical analysis
  • Apremilast + Standard of Care vs Apremilast Placebo Control · Regression, Logistic · p = 0.4846 · Risk difference (rd): -2.9 · 95% CI -11.2 to 5.3Risk difference is from a logistic regression including baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.
  • Apremilast + Standard of Care vs Apremilast Placebo Control · Odds ratio (or): 0.84 · 95% CI 0.51 to 1.37Odds ratio (apremilast vs. placebo) is from a logistic regression including baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.
SecondaryApremilast Sub-protocol: Percentage of Participants Who Died Before or on Day 29

All-cause mortality is death due to any cause. Participants with an unknown alive/death status on Day 29 were considered alive for this analysis, with the exception of patients with a score of 7 who were discharged to hospice care before or on Day 29.

Time frame:
Day 1 to Day 29
Reported as:
Number · percentage of participants
Apremilast Sub-protocol: Percentage of Participants Who Died Before or on Day 29
percentage of participantsApremilast + Standard of CareApremilast Placebo Control
Apremilast Sub-protocol: Percentage of Participants Who Died Before or on Day 2917.517.4
Statistical analysis
  • Apremilast + Standard of Care vs Apremilast Placebo Control · Regression, Logistic · p = 0.9665 · Risk difference (rd): 0.2 · 95% CI -7.3 to 7.6Risk difference is from a logistic regression including baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.
  • Apremilast + Standard of Care vs Apremilast Placebo Control · Odds ratio (or): 1.01 · 95% CI 0.59 to 1.74Odds ratio (apremilast vs. placebo) is from a logistic regression including the baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.
SecondaryApremilast Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29

The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities Participants with a score of 7 who were discharged to hospice care are counted with participants with a score of 1 (death) for this endpoint.

Time frame:
Day 8, Day 15, and Day 29
Reported as:
Count of participants · Participants
Apremilast Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29
ParticipantsApremilast + Standard of CareApremilast Placebo Control
Day 8 — 1 (Death or discharged to hospice care)118
Day 8 — 2 (Hospitalized on invasive mechanical ventilation or ECMO)2220
Day 8 — 3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices)2526
Day 8 — 4 (Hospitalized, requiring supplemental oxygen)2626
Day 8 — 5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care)3140
Day 8 — 6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care)01
Day 8 — 7 (Not hospitalized, limitation on activities and/or requiring home oxygen)3633
Day 8 — 8 (Not hospitalized, no limitations on activities)3834
Day 8 — Missing52
Day 15 — 1 (Death or discharged to hospice care)2224
Day 15 — 2 (Hospitalized on invasive mechanical ventilation or ECMO)1613
Day 15 — 3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices)99
Day 15 — 4 (Hospitalized, requiring supplemental oxygen)98
Day 15 — 5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care)105
Day 15 — 6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care)02
Day 15 — 7 (Not hospitalized, limitation on activities and/or requiring home oxygen)4648
Day 15 — 8 (Not hospitalized, no limitations on activities)7879
Day 15 — Missing42
Day 29 — 1 (Death or discharged to hospice care)3431
Day 29 — 2 (Hospitalized on invasive mechanical ventilation or ECMO)66
Day 29 — 3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices)03
Day 29 — 4 (Hospitalized, requiring supplemental oxygen)61
Day 29 — 5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care)01
Day 29 — 6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care)02
Day 29 — 7 (Not hospitalized, limitation on activities and/or requiring home oxygen)3440
Day 29 — 8 (Not hospitalized, no limitations on activities)110104
Day 29 — Missing42
Statistical analysis
  • Apremilast + Standard of Care vs Apremilast Placebo Control · Proportional odds model · p = 0.9119 · Odds ratio (or): 1.02 · 95% CI 0.71 to 1.46Odds ratio (Apremilast vs. Placebo) from a proportional odds model including the baseline clinical severity of 2 on the 8-point ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), region, and treatment arm as factors.
  • Apremilast + Standard of Care vs Apremilast Placebo Control · Proportional odds model · p = 0.6475 · Odds ratio (or): 1.09 · 95% CI 0.75 to 1.58Odds ratio (Apremilast vs. Placebo) from a proportional odds model including the baseline clinical severity of 2 on the 8-point ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), region, and treatment arm as factors.
  • Apremilast + Standard of Care vs Apremilast Placebo Control · Proportional odds model · p = 0.9071 · Odds ratio (or): 0.98 · 95% CI 0.64 to 1.48Odds ratio (Apremilast vs. Placebo) from a proportional odds model including the baseline clinical severity of 2 on the 8-point ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), region, and treatment arm as factors.
SecondaryApremilast Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-Point Ordinal Scale From Baseline to Day 29

The worst post-baseline score (lower scores are worse) through Day 29 in the clinical severity status 8-point ordinal scale, derived from all scores recorded after baseline up to and including Day 29. Participants with a score of 7 discharged to hospice care are considered as having a score of 1 (death) instead of a score of 7 for this endpoint. The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities

Time frame:
Day 2 to Day 29
Reported as:
Count of participants · Participants
Apremilast Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-Point Ordinal Scale From Baseline to Day 29
ParticipantsApremilast + Standard of CareApremilast Placebo Control
1 (Death or discharged to hospice care)3431
2 (Hospitalized on invasive mechanical ventilation or ECMO)1310
3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices)3743
4 (Hospitalized, requiring supplemental oxygen)7562
5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care)2135
6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care)00
7 (Not hospitalized, limitation on activities and/or requiring home oxygen)52
8 (Not hospitalized, no limitations on activities)55
Missing42
Statistical analysis
  • Apremilast + Standard of Care vs Apremilast Placebo Control · Proportional odds model · p = 0.4507 · Odds ratio (or): 1.15 · 95% CI 0.80 to 1.66Odds ratio (Apremilast vs. Placebo) from a proportional odds model including the baseline clinical severity of 2 on the 8-point ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), region, and treatment arm as factors.
SecondaryApremilast Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29

Number of ICU days is the sum of the duration of any episode of ICU admission between Day 1 and Day 29, both inclusive. The number of ICU days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30 (worst possible outcome).

Time frame:
Day 1 to Day 29
Reported as:
Count of participants · Participants
Apremilast Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29
ParticipantsApremilast + Standard of CareApremilast Placebo Control
0 days124122
1 day42
2 days21
3 days24
4 days01
5 days41
6 days23
7 days42
8 days24
9 days11
10 days11
11 days01
12 days11
13 days02
14 days20
15 days01
17 days02
18 days01
20 days01
21 days02
23 days02
25 days10
27 days11
28 days10
29 days82
30 days (death or discharged to hospice care)3432
Statistical analysis
  • Apremilast + Standard of Care vs Apremilast Placebo Control · Proportional odds model · p = 0.9741 · Odds ratio (or): 0.99 · 95% CI 0.64 to 1.53Odds ratio (Apremilast vs. Placebo) from a proportional odds model including the baseline clinical severity of 2 on the 8-point ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), region, and treatment arm as factors.
SecondaryApremilast Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29

Number of invasive mechanical ventilator days is the sum of the duration of any episode of invasive mechanical ventilator admission between Day 1 and Day 29, both inclusive. The number of invasive mechanical ventilator days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30.

Time frame:
Day 1 to Day 29
Reported as:
Count of participants · Participants
Apremilast Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29
ParticipantsApremilast + Standard of CareApremilast Placebo Control
0 days147147
6 days11
9 days10
10 days10
11 days11
12 days01
13 days20
16 days02
18 days01
19 days10
22 days10
23 days01
24 days01
25 days31
26 days11
29 days10
30 days (death or discharged to hospice care)3433
Statistical analysis
  • Apremilast + Standard of Care vs Apremilast Placebo Control · Proportional odds model · p = 0.8754 · Odds ratio (or): 1.04 · 95% CI 0.64 to 1.70Odds ratio (Apremilast vs. Placebo) from a proportional odds model including the baseline clinical severity of 2 on the 8-point ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), region, and treatment arm as factors.
SecondaryApremilast Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery at Days 8, 15, and 29

Clinical recovery is defined as being fit for discharge, i.e., the achievement of a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who discontinued the study on or before Days 8, 15, or 29 or with a missing clinical recovery status were considered as not having clinical recovery at each respective time point. Clinical severity status 8-point ordinal scale: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities

Time frame:
Day 8, Day 15, and Day 29
Reported as:
Number · percentage of participants
Apremilast Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery at Days 8, 15, and 29
percentage of participantsApremilast + Standard of CareApremilast Placebo Control
Day 836.635.8
Day 1557.760.0
Day 2966.072.1
Statistical analysis
  • Apremilast + Standard of Care vs Apremilast Placebo Control · Regression, Logistic · p = 0.9695 · Risk difference (rd): 0.2 · 95% CI -8.7 to 9.1Risk difference is from a logistic regression including the baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.
  • Apremilast + Standard of Care vs Apremilast Placebo Control · Odds ratio (or): 1.01 · 95% CI 0.64 to 1.59Odds ratio (apremilast vs. placebo) is from a logistic regression including the baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.
  • Apremilast + Standard of Care vs Apremilast Placebo Control · Regression, Logistic · p = 0.6236 · Risk difference (rd): -2.4 · 95% CI -11.9 to 7.1Risk difference is from a logistic regression including the baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.
  • Apremilast + Standard of Care vs Apremilast Placebo Control · Odds ratio (or): 0.90 · 95% CI 0.59 to 1.37Odds ratio (apremilast vs. placebo) is from a logistic regression including the baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.
  • Apremilast + Standard of Care vs Apremilast Placebo Control · Regression, Logistic · p = 0.1664 · Risk difference (rd): -6.2 · 95% CI -14.9 to 2.5Risk difference is from a logistic regression including the baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.
  • Apremilast + Standard of Care vs Apremilast Placebo Control · Odds ratio (or): 0.72 · 95% CI 0.45 to 1.15Odds ratio (apremilast vs. placebo) is from a logistic regression including the baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.
SecondaryApremilast Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery

Sustained clinical recovery is defined as being fit for discharge (achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale) by Day 29, without re-hospitalization by Day 60. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who died or discontinued from study or with a missing clinical recovery status at Day 60 were not considered having sustained clinical recovery. Clinical severity status 8-point ordinal scale: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities

Time frame:
Day 60
Reported as:
Number · percentage of participants
Apremilast Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery
percentage of participantsApremilast + Standard of CareApremilast Placebo Control
Apremilast Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery66.066.3
Statistical analysis
  • Apremilast + Standard of Care vs Apremilast Placebo Control · Regression, Logistic · p = 0.9043 · Risk difference (rd): -0.5 · 95% CI -9.3 to 8.3Risk difference is from a logistic regression including the baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.
  • Apremilast + Standard of Care vs Apremilast Placebo Control · Odds ratio (or): 0.97 · 95% CI 0.62 to 1.54Odds ratio (apremilast vs. placebo) is from a logistic regression including the baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.
SecondaryApremilast Sub-protocol: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to study treatment. A TEAE is an AE that occurs after the first dose of study drug. A serious AE is any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, resulted in persistent disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may jeopardize the patient or require intervention to prevent an outcome listed above. The Investigator assessed the intensity of each AE according to the CTCAE grades: * Grade 1 Mild; asymptomatic or mild symptoms; * Grade 2 Moderate; minimal, local or noninvasive intervention indicated; * Grade 3 Severe or medically significant, not immediately life-threatening; * Grade 4 Life-threatening; urgent intervention indicated; * Grade 5 Death due to AE.

Time frame:
From first dose of study drug to end of study (Day 60)
Reported as:
Count of participants · Participants
Apremilast Sub-protocol: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsApremilast + Standard of CareApremilast Placebo ControlApremilast Placebo + Standard of Care
Any treatment-emergent adverse event (TEAE)102103100
TEAE with a CTCAE grade ≥ 3485754
Serious TEAE515755
TEAE leading to dose modification1666
TEAE leading to discontinuation of study drug91211
SecondaryZilucoplan Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29

Oxygen-free recovery at Day 29 is defined as being alive, discharged, and not receiving supplemental oxygen at Day 29. Participants who reached a score of 7 on the ordinal scale for clinical severity who were discharged to hospice care before or on Day 29 were considered as not discharged at Day 29. Participants with a missing oxygen-free recovery status at Day 29 were considered as not having an oxygen-free recovery.

Time frame:
Day 29
Reported as:
Number · percentage of participants
Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29
percentage of participantsZilucoplan + Standard of CareZilucoplan Placebo Control
Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 2954.0 (43.74 to 64.02)60.0 (48.04 to 71.15)
SecondaryZilucoplan Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29

Fit for discharge is defined as achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with an ordinal scale score of 7 must not have been discharged to hospice care to be considered as fit for discharge. Participants with a missing clinical severity score at Day 29 were considered as not having met the event at Day 29. The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities

Time frame:
Baseline (Day 1) and Day 29
Reported as:
Number · percentage of participants
Zilucoplan Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29
percentage of participantsZilucoplan + Standard of CareZilucoplan Placebo Control
Zilucoplan Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 2966.0 (55.85 to 75.18)69.3 (57.62 to 79.47)
SecondaryZilucoplan Sub-protocol: Percentage of Participants Who Died Before or on Day 29

All-cause mortality is death due to any cause. Participants with an unknown alive/death status on Day 29 were considered alive for this analysis, with the exception of patients with a score of 7 who were discharged to hospice care before or on Day 29.

Time frame:
Day 1 to Day 29
Reported as:
Number · percentage of participants
Zilucoplan Sub-protocol: Percentage of Participants Who Died Before or on Day 29
percentage of participantsZilucoplan + Standard of CareZilucoplan Placebo Control
Zilucoplan Sub-protocol: Percentage of Participants Who Died Before or on Day 2918.0 (11.03 to 26.95)24.0 (14.89 to 35.25)
SecondaryZilucoplan Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29

The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities Participants with a score of 7 who were discharged to hospice care are counted with participants with a score of 1 (death) for this endpoint.

Time frame:
Day 8, Day 15, and Day 29
Reported as:
Count of participants · Participants
Zilucoplan Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29
ParticipantsZilucoplan + Standard of CareZilucoplan Placebo Control
Day 8 — 1 (Death or discharged to hospice care)55
Day 8 — 2 (Hospitalized on invasive mechanical ventilation or ECMO)2414
Day 8 — 3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices)128
Day 8 — 4 (Hospitalized, requiring supplemental oxygen)1614
Day 8 — 5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care)510
Day 8 — 6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care)01
Day 8 — 7 (Not hospitalized, limitation on activities and/or requiring home oxygen)229
Day 8 — 8 (Not hospitalized, no limitations on activities)1112
Day 8 — Missing52
Day 15 — 1 (Death or discharged to hospice care)814
Day 15 — 2 (Hospitalized on invasive mechanical ventilation or ECMO)167
Day 15 — 3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices)33
Day 15 — 4 (Hospitalized, requiring supplemental oxygen)106
Day 15 — 5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care)22
Day 15 — 6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care)01
Day 15 — 7 (Not hospitalized, limitation on activities and/or requiring home oxygen)2514
Day 15 — 8 (Not hospitalized, no limitations on activities)3126
Day 15 — Missing52
Day 29 — 1 (Death or discharged to hospice care)1418
Day 29 — 2 (Hospitalized on invasive mechanical ventilation or ECMO)102
Day 29 — 3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices)11
Day 29 — 4 (Hospitalized, requiring supplemental oxygen)51
Day 29 — 5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care)10
Day 29 — 6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care)02
Day 29 — 7 (Not hospitalized, limitation on activities and/or requiring home oxygen)2014
Day 29 — 8 (Not hospitalized, no limitations on activities)4435
Day 29 — Missing52
SecondaryZilucoplan Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-Point Ordinal Scale From Baseline to Day 29

The worst post-baseline score (lower scores are worse) through Day 29 in the clinical severity status 8-point ordinal scale scores, derived from all scores recorded after baseline up to and including Day 29. Participants with a score of 7 discharged to hospice care were considered as having a score of 1 (death) instead of a score of 7 for this endpoint. The clinical severity status 8-point ordinal scale scores scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities

Time frame:
Day 2 to Day 29
Reported as:
Count of participants · Participants
Zilucoplan Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-Point Ordinal Scale From Baseline to Day 29
ParticipantsZilucoplan + Standard of CareZilucoplan Placebo Control
1 (Death or discharged to hospice care)1418
2 (Hospitalized on invasive mechanical ventilation or ECMO)216
3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices)2412
4 (Hospitalized, requiring supplemental oxygen)3029
5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care)57
6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care)00
7 (Not hospitalized, limitation on activities and/or requiring home oxygen)10
8 (Not hospitalized, no limitations on activities)01
Missing52
SecondaryZilucoplan Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29

Number of ICU days is the sum of the duration of any episode of ICU admission between Day 1 and Day 29, both inclusive. The number of ICU days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30 (worst possible outcome).

Time frame:
Day 1 to Day 29
Reported as:
Count of participants · Participants
Zilucoplan Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29
ParticipantsZilucoplan + Standard of CareZilucoplan Placebo Control
0 days5634
1 day02
3 days22
4 days01
5 days11
6 days13
7 days40
8 days04
9 days31
10 days01
11 days10
13 days12
14 days10
15 days01
17 days11
18 days10
21 days02
22 days10
25 days10
26 days10
29 days82
30 days (death or discharged to hospice care)1718
SecondaryZilucoplan Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29

Number of invasive mechanical ventilator days is the sum of the duration of any episode of invasive mechanical ventilator admission between Day 1 and Day 29, both inclusive. The number of invasive mechanical ventilator days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30.

Time frame:
Day 1 to Day 29
Reported as:
Count of participants · Participants
Zilucoplan Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29
ParticipantsZilucoplan + Standard of CareZilucoplan Placebo Control
0 days6752
6 days01
7 days40
9 days10
10 days10
12 days01
13 days10
16 days01
18 days10
22 days10
24 days11
25 days10
26 days11
27 days10
28 days10
29 days10
30 days (death or discharged to hospice care)1818
SecondaryZilucoplan Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery by Days 8, 15, and 29

Clinical recovery is defined as being fit for discharge, i.e., the achievement of a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who discontinued the study on or before Days 8, 15, or 29 or with a missing clinical recovery status were considered as not having clinical recovery at each respective time point. Clinical severity status 8-point ordinal scale: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities

Time frame:
Day 8, Day 15, and Day 29
Reported as:
Number · percentage of participants
Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery by Days 8, 15, and 29
percentage of participantsZilucoplan + Standard of CareZilucoplan Placebo Control
Day 833.0 (23.92 to 43.12)30.7 (20.53 to 42.38)
Day 1553.0 (42.76 to 63.06)53.3 (41.45 to 64.95)
Day 2960.0 (49.72 to 69.67)66.7 (54.83 to 77.14)
SecondaryZilucoplan Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery

Sustained clinical recovery is defined as being fit for discharge (achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale) by Day 29, without re-hospitalization by Day 60. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who died or discontinued from study or with a missing clinical recovery status at Day 60 were not considered having sustained clinical recovery. Clinical severity status 8-point ordinal scale: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities

Time frame:
Day 60
Reported as:
Number · percentage of participants
Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery
percentage of participantsZilucoplan + Standard of CareZilucoplan Placebo Control
Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery55.0 (44.73 to 64.97)64.0 (52.09 to 74.77)
SecondaryZilucoplan Sub-protocol: Number of Participants With Treatment-emergent Adverse Events

An adverse event is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to study treatment. A TEAE is an AE that occurs after the first dose of study drug. A serious AE is any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, resulted in persistent disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may jeopardize the patient or require intervention to prevent an outcome listed above. The Investigator assessed the intensity of each AE according to the CTCAE grades: * Grade 1 Mild; asymptomatic or mild symptoms; * Grade 2 Moderate; minimal, local or noninvasive intervention indicated; * Grade 3 Severe or medically significant, not immediately life-threatening; * Grade 4 Life-threatening; urgent intervention indicated; * Grade 5 Death due to AE.

Time frame:
From first dose of study drug to end of study (Day 60)
Reported as:
Count of participants · Participants
Zilucoplan Sub-protocol: Number of Participants With Treatment-emergent Adverse Events
ParticipantsZilucoplan+ Standard of CareZilucoplan Placebo ControlZilucoplan Placebo + Standard of Care
Any treatment-emergent adverse event (TEAE)65474
TEAE with a CTCAE grade ≥ 334293
Serious TEAE31292
TEAE leading to dose modification050
TEAE leading to discontinuation of study drug751

Adverse events

Collected over From first dose of study drug to end of study (Day 60).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lanadelumab + SoC8/28 (28.6%)11/27 (40.7%)12/27 (44.4%)
Lanadelumab Placebo + SoC1/1 (100%)1/1 (100%)1/1 (100%)
Apremilast + SoC37/194 (19.1%)51/189 (27%)63/189 (33.3%)
Apremilast Placebo + SoC35/184 (19%)55/182 (30.2%)50/182 (27.5%)
Zilucoplan + SoC20/100 (20%)31/95 (32.6%)46/95 (48.4%)
Zilucoplan Placebo + SoC3/8 (37.5%)2/7 (28.6%)4/7 (57.1%)
Most frequent serious events
Showing 10 of 72
Most frequent serious events
EventLanadelumab + SoCLanadelumab Placebo + SoCApremilast + SoCApremilast Placebo + SoCZilucoplan + SoCZilucoplan Placebo + SoC
COVID-19 pneumoniaInfections and infestations3/271/16/1896/1822/950/7
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/270/111/1896/1825/951/7
Respiratory failureRespiratory, thoracic and mediastinal disorders2/270/114/18910/1828/951/7
Septic shockInfections and infestations2/270/112/18910/1828/950/7
Acute kidney injuryRenal and urinary disorders1/270/17/1894/1827/950/7
Cardio-respiratory arrestCardiac disorders1/270/12/1892/1822/950/7
Sinus bradycardiaCardiac disorders1/270/10/1890/1820/950/7
Pneumonia bacterialInfections and infestations1/270/11/1891/1822/950/7
SepsisInfections and infestations1/270/13/1893/1821/950/7
Staphylococcal infectionInfections and infestations1/270/10/1890/1820/950/7
Most frequent other events
Showing 10 of 37
Most frequent other events
EventLanadelumab + SoCLanadelumab Placebo + SoCApremilast + SoCApremilast Placebo + SoCZilucoplan + SoCZilucoplan Placebo + SoC
AnaemiaBlood and lymphatic system disorders2/271/19/1894/1829/950/7
LeukopeniaBlood and lymphatic system disorders0/271/10/1890/1820/950/7
BradycardiaCardiac disorders0/271/11/1893/1821/950/7
Cardiac failure congestiveCardiac disorders0/271/10/1890/1820/950/7
TachycardiaCardiac disorders1/271/13/1892/1824/950/7
Pneumonia klebsiellaInfections and infestations0/271/10/1892/1822/950/7
Soft tissue injuryInjury, poisoning and procedural complications0/271/10/1890/1820/950/7
Oxygen saturation decreasedInvestigations0/271/10/1890/1820/950/7
AcidosisMetabolism and nutrition disorders0/271/10/1890/1820/950/7
HypernatraemiaMetabolism and nutrition disorders2/271/14/1893/1823/951/7

Baseline characteristics

Baseline characteristics are reported for the full analysis set, which includes all participants who were randomized to the sub-protocol candidate agent arm as well as all participants who were randomized to any placebo arm included in the control arm of the candidate agent. The Total number of participants (621) includes participants randomized to placebo and included in more than one placebo control group (106 participants); 515 unique participants were enrolled in the study.

Age, Continuous
Age, Continuous(years)Lanadelumab + Standard of CareLanadelumab Placebo ControlApremilast + Standard of CareApremilast Placebo ControlZilucoplan + Standard of CareZilucoplan Placebo +ControlTotal
Lanadelumab Sub-protocol53.4 ± 15.3459.6 ± 13.50————56.8 ± 14.57
Apremilast Sub-protocol——57.2 ± 13.8455.7 ± 13.37——56.5 ± 13.61
Zilucoplan Sub-protocol————53.2 ± 14.1358.4 ± 13.6255.4 ± 14.11
Age, Customized
Age, Customized(Participants)Lanadelumab + Standard of CareLanadelumab Placebo ControlApremilast + Standard of CareApremilast Placebo ControlZilucoplan + Standard of CareZilucoplan Placebo +ControlTotal
Lanadelumab Sub-protocol — ≥ 18 to ≤ 49 years138————21
Lanadelumab Sub-protocol — ≥ 50 to ≤ 64 years715————22
Lanadelumab Sub-protocol — ≥ 65 to ≤ 84 years810————18
Lanadelumab Sub-protocol — ≥ 85 years01————1
Apremilast Sub-protocol — ≥ 18 to ≤ 49 years——5156——107
Apremilast Sub-protocol — ≥ 50 to ≤ 64 years——7681——157
Apremilast Sub-protocol — ≥ 65 to ≤ 84 years——6452——116
Apremilast Sub-protocol — ≥ 85 years——31——4
Zilucoplan Sub-protocol — ≥ 18 to ≤ 49 years————451964
Zilucoplan Sub-protocol — ≥ 50 to ≤ 64 years————362965
Zilucoplan Sub-protocol — ≥ 65 to ≤ 84 years————162642
Zilucoplan Sub-protocol — ≥ 85 years————314
Sex: Female, Male
Sex: Female, Male(Participants)Lanadelumab + Standard of CareLanadelumab Placebo ControlApremilast + Standard of CareApremilast Placebo ControlZilucoplan + Standard of CareZilucoplan Placebo +ControlTotal
Lanadelumab Sub-protocol — Female119000020
Lanadelumab Sub-protocol — Male1725000042
Apremilast Sub-protocol — Female00847200156
Apremilast Sub-protocol — Male0011011800228
Zilucoplan Sub-protocol — Female0000342862
Zilucoplan Sub-protocol — Male00006647113
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lanadelumab + Standard of CareLanadelumab Placebo ControlApremilast + Standard of CareApremilast Placebo ControlZilucoplan + Standard of CareZilucoplan Placebo +ControlTotal
Lanadelumab Sub-protocol — Hispanic or Latino1819————37
Lanadelumab Sub-protocol — Not Hispanic or Latino1015————25
Lanadelumab Sub-protocol — Unknown or Not Reported00————0
Apremilast Sub-protocol — Hispanic or Latino——7572——147
Apremilast Sub-protocol — Not Hispanic or Latino——108112——220
Apremilast Sub-protocol — Unknown or Not Reported——116——17
Zilucoplan Sub-protocol — Hispanic or Latino————653297
Zilucoplan Sub-protocol — Not Hispanic or Latino————354378
Zilucoplan Sub-protocol — Unknown or Not Reported————000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lanadelumab + Standard of CareLanadelumab Placebo ControlApremilast + Standard of CareApremilast Placebo ControlZilucoplan + Standard of CareZilucoplan Placebo +ControlTotal
Lanadelumab Sub-protocol — American Indian or Alaska Native10——315
Lanadelumab Sub-protocol — Asian00——358
Lanadelumab Sub-protocol — Native Hawaiian or Other Pacific Islander00——000
Lanadelumab Sub-protocol — Black or African American32——5515
Lanadelumab Sub-protocol — White2028——7558181
Lanadelumab Sub-protocol — More than one race21——8213
Lanadelumab Sub-protocol — Unknown or Not Reported23——6415
Apremilast Sub-protocol — American Indian or Alaska Native——01——1
Apremilast Sub-protocol — Asian——117——18
Apremilast Sub-protocol — Native Hawaiian or Other Pacific Islander——01——1
Apremilast Sub-protocol — Black or African American——99——18
Apremilast Sub-protocol — White——151151——302
Apremilast Sub-protocol — More than one race——47——11
Apremilast Sub-protocol — Unknown or Not Reported——1914——33
Zilucoplan Sub-protocol — American Indian or Alaska Native————314
Zilucoplan Sub-protocol — Asian————358
Zilucoplan Sub-protocol — Native Hawaiian or Other Pacific Islander————000
Zilucoplan Sub-protocol — Black or African American————5510
Zilucoplan Sub-protocol — White————7558133
Zilucoplan Sub-protocol — More than one race————8210
Zilucoplan Sub-protocol — Unknown or Not Reported————6410
Region
Region(Participants)Lanadelumab + Standard of CareLanadelumab Placebo ControlApremilast + Standard of CareApremilast Placebo ControlZilucoplan + Standard of CareZilucoplan Placebo +ControlTotal
Lanadelumab Sub-protocol — North America99————18
Lanadelumab Sub-protocol — Latin America1820————38
Lanadelumab Sub-protocol — Eastern Europe00————0
Lanadelumab Sub-protocol — Rest of the World15————6
Apremilast Sub-protocol — North America——5360——113
Apremilast Sub-protocol — Latin America——6050——110
Apremilast Sub-protocol — Eastern Europe——5153——104
Apremilast Sub-protocol — Rest of the World——3027——57
Zilucoplan Sub-protocol — North America————261036
Zilucoplan Sub-protocol — Latin America————653398
Zilucoplan Sub-protocol — Eastern Europe————61420
Zilucoplan Sub-protocol — Rest of the World————31821
Remdesivir Use at Baseline
Remdesivir Use at Baseline(Participants)Lanadelumab + Standard of CareLanadelumab Placebo ControlApremilast + Standard of CareApremilast Placebo ControlZilucoplan + Standard of CareZilucoplan Placebo +ControlTotal
Lanadelumab Sub-protocol — Yes75————12
Lanadelumab Sub-protocol — No2129————50
Apremilast Sub-protocol — Yes——4544——89
Apremilast Sub-protocol — No——149146——295
Zilucoplan Sub-protocol — Yes————22931
Zilucoplan Sub-protocol — No————7866144
Clinical Severity Score of 2
Clinical Severity Score of 2(Participants)Lanadelumab + Standard of CareLanadelumab Placebo ControlApremilast + Standard of CareApremilast Placebo ControlZilucoplan + Standard of CareZilucoplan Placebo +ControlTotal
Lanadelumab Sub-protocol — Yes (Grade 2)34————7
Lanadelumab Sub-protocol — No (Grade 3-5)2530————55
Apremilast Sub-protocol — Yes (Grade 2)——119——20
Apremilast Sub-protocol — No (Grade 3-5)——183181——364
Zilucoplan Sub-protocol — Yes (Grade 2)————8614
Zilucoplan Sub-protocol — No (Grade 3-5)————9269161
08

Study locations

59 sites
  • Pinnacle Research Group LLC
    Anniston, Alabama 36207, United States
  • Good Samaritan Hospital
    Bakersfield, California 93309, United States
  • Sharp Chula Vista Medical Center
    Chula Vista, California 91910, United States
  • El Centro Regional Medical Center
    El Centro, California 92243, United States
  • University of California Irvine Medical Center
    Orange, California 92868, United States
  • Riverside Community Hospital
    Riverside, California 92501-4135, United States
  • National Institute of Clinical Research
    S. El Monte, California 91733, United States
  • University of California Davis Health System
    Sacramento, California 95817, United States
  • UF Health Shands Hospital
    Gainesville, Florida 32610, United States
  • Memorial Hospital Jacksonville
    Jacksonville, Florida 32216, United States
  • Grady Health System
    Atlanta, Georgia 30303, United States
  • Great Lakes Clinical Trials
    Chicago, Illinois 60640, United States
  • The University of Iowa
    Iowa City, Iowa 52242, United States
  • Harper University Hospital
    Detroit, Michigan 48201-2018, United States
  • Sinai Grace Hospital
    Detroit, Michigan 48235, United States
  • Detroit Receiving Hospital
    Royal Oak, Michigan 48073, United States
  • University of Tennessee Health Sciences Center
    Memphis, Tennessee 38103, United States
  • Medical City Ft. Worth
    Fort Worth, Texas 76104, United States
  • University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • Texoma Medical Center
    Sherman, Texas 75090, United States
  • MultiCare Health System Institute for Research and Innovation
    Tacoma, Washington 98405, United States
  • Hospital San Juan de Dios
    Ramos Mejia, Buenos Aires 1704, Argentina
  • Hospital General de Agudos Dr. J. M. Ramos Mejia
    Ciudad Autonoma Buenos Aires, C1221ADC, Argentina
  • Hospital General de Agudos Dr. Ignacio Pirovano
    Ciudad Autonoma Buenos Aires, C1430BKC, Argentina
  • Clinica Adventista Belgrano
    Ciudad Autonoma Buenos Aires, C1430EGF, Argentina
  • Hospital Italiano de Rosario
    Rosario, 2000, Argentina
  • Chronos Pesquisa Clinica
    Brasília, Distrito Federal 72.145-450, Brazil
  • HC-UFG - Hospital das Clínicas da Universidade Federal de Goiás
    Goiânia, Goiás 74605-020, Brazil
  • Santa Casa de Misericórdia de Belo Horizonte
    Belo Horizonte, Minas Gerais 30150-221, Brazil
  • Hospital de Clínicas de Porto Alegre
    Porto Alegre, Rio Grande Do Sul 90035-903, Brazil
  • UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu
    Botucatu, Sao Paulo 18618-970, Brazil
  • Praxis Pesquisa Médica
    Santo André, Sao Paulo 09090-790, Brazil
  • Hospital Base Osorno
    Osorno, 5290000, Chile
  • Hospital General de Tijuana
    Tijuana, Baja California Norte 22000, Mexico
  • Hospital Civil de Guadalajara Dr. Juan I. Menchaca
    Guadalajara, Jalisco 44340, Mexico
  • Universidad Autonoma de Nuevo Leon, Hospital Universitario Dr. Jose Eleuterio Gonzalez
    Monterrey, Nuevo León 64460, Mexico
  • Hospital Civil de Culiacan
    Culiacán, Sinaloa 80030, Mexico
  • TSBIH "Krasnoyarsk Interdistrict Clinical Hospital of Emergency Medical Care n.a. N.S. Karpovich
    Krasnoyarsk, 660062, Russian Federation
  • SBIH of Moscow "Infectious Clinical Hospital # 1 of Department of Healthcare of Moscow"
    Moscow, 125367, Russian Federation
  • SPb SBIH "Alexandrovskaya City Hospital"
    Saint Petersburg, 193312, Russian Federation
  • St-George Hospital
    Saint Petersburg, 194354, Russian Federation
  • SPb SBIH "Nikolaevskaya Hospital"
    Saint Petersburg, 198510, Russian Federation
  • SPb SBIH "City Pokrovskaya Hospital"
    Saint Petersburg, 199106, Russian Federation
  • SPb SBIH "City Hospital # 40 of Kurortnyi region"
    Sestroretsk, 197706, Russian Federation
  • Nelson Mandela Academic Clinical Research Unit (NeMACRU)
    Mthatha, Eastern Cape 5100, South Africa
  • Johese Clinical Research: Unitas
    Centurion, Gauteng 0157, South Africa
  • MERC SiReN
    Johannesburg, Gauteng 2193, South Africa
  • Drs Sarvan and Moodley
    Durban, KwaZulu-Natal 4320, South Africa
  • Tread Research
    Cape Town, Western Cape 7500, South Africa
  • Tiervlei Trial Centre
    Cape Town, Western Cape 7530, South Africa
  • 2 Military Hospital Internal Medicine
    Cape Town, Western Cape 7800, South Africa
  • Dr JM Engelbrecht Trial Site
    Somerset West, Western Cape 7130, South Africa
  • Clinical Projects Research SA (PTY) LTD
    Worcester, Western Cape 6850, South Africa
  • Communal Noncommercial Profit "Clinical City Hospital 16 of Dnipro Regional Council"
    Dnipro, 49069, Ukraine
  • CNE of Kharkov RC Reg Cl Infectious Hospital
    Kharkiv, 61096, Ukraine
  • Communal Non-Commercial Medical Enterprise "O.T.Bohayevskyi Kremenchuk City Hospital #1"
    Kremenchuk, 39623, Ukraine
  • City Clinical infectious Hospital
    Odesa, 65026, Ukraine
  • Municipal Non-Profit Enterprise Central City Hospital Of Rivne City Council
    Rivne, 33017, Ukraine
  • CCH #1 Vinnytsia M.I.Pyrogov NMU Ch of Infectious Diseases
    Vinnytsia, 21029, Ukraine
09

References and documents

Publications

  • Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2. PubMed 34473343 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Aug 2021, 8 months.

Results were first posted in Jun 2022, 10 months after primary completion.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 8 months is close to that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2020
First posted
Oct 19, 2020
StartActual
Nov 24, 2020
Primary completionActual
Aug 3, 2021
CompletionActual
Aug 3, 2021
Results first posted
Jun 29, 2022
Last update
Jun 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04590586
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 19, 2020
Start date
Nov 24, 2020
Primary completion
Aug 3, 2021
Completion
Aug 3, 2021
Results posted
Jun 29, 2022
Last update
Jun 29, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Apremilast · Lanadelumab · Zilucoplan

Start the discussion